|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dat T, Matsuo T, Yoshimaru T, Kakiuchi S,
Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S and Katagiri T:
Identification of genes potentially involved in bone metastasis by
genome-wide gene expression profile analysis of non-small cell lung
cancer in mice. Int J Oncol. 40:1455–1469. 2012.PubMed/NCBI
|
|
4
|
Langley RR and Fidler IJ: The seed and
soil hypothesis revisited - the role of tumor-stroma interactions
in metastasis to different organs. Int J Cancer. 128:2527–2535.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Larsen JE and Minna JD: Molecular biology
of lung cancer: Clinical implications. Clin Chest Med. 32:703–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miele E, Spinelli GP, Miele E, Di Fabrizio
E, Ferretti E, Tomao S and Gulino A: Nanoparticle-based delivery of
small interfering RNA: Challenges for cancer therapy. Int J
Nanomedicine. 7:3637–3657. 2012.PubMed/NCBI
|
|
7
|
Joo MK, Yhee JY, Kim SH and Kim K: The
potential and advances in RNAi therapy: Chemical and structural
modifications of siRNA molecules and use of biocompatible
nanocarriers. J Control Release. 193:113–121. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Y, Gu H, Zhang DS, Li F, Liu T and
Xia W: Highly effective inhibition of lung cancer growth and
metastasis by systemic delivery of siRNA via multimodal mesoporous
silica-based nanocarrier. Biomaterials. 35:10058–10069. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y,
Li H, Wang L, Wang X and Zhao C: MiR-204 inhibits human NSCLC
metastasis through suppression of NUAK1. Br J Cancer.
111:2316–2327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang J, Lee SY, Lee SY, Kim YJ, Park JY,
Kwon SJ, Na MJ, Lee EJ, Jeon HS and Son JW: MicroRNA-99b acts as a
tumor suppressor in non-small cell lung cancer by directly
targeting fibroblast growth factor receptor 3. Exp Ther Med.
3:149–153. 2012.PubMed/NCBI
|
|
11
|
Lamont FR, Tomlinson DC, Cooper PA,
Shnyder SD, Chester JD and Knowles MA: Small molecule FGF receptor
inhibitors block FGFR-dependent urothelial carcinoma growth in
vitro and in vivo. Br J Cancer. 104:75–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smid M, Wang Y, Klijn JG, Sieuwerts AM,
Zhang Y, Atkins D, Martens JW and Foekens JA: Genes associated with
breast cancer metastatic to bone. J Clin Oncol. 24:2261–2267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang S, Dong S, Gu TL, Guo A, Cohen MS,
Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, et al:
FGFR3 activates RSK2 to mediate hematopoietic transformation
through tyrosine phosphorylation of RSK2 and activation of the
MEK/ERK pathway. Cancer Cell. 12:201–214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Lu H, Urvalek AM, Li T, Yu L,
Lamar J, DiPersio CM, Feustel PJ and Zhao J: KLF8 promotes human
breast cancer cell invasion and metastasis by transcriptional
activation of MMP9. Oncogene. 30:1901–1911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tu CL and You M: Obligatory roles of
filamin A in E-cadherin-mediated cell-cell adhesion in epidermal
keratinocytes. J Dermatol Sci. 73:142–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang XB, Wang JS, Liu DH, Yuan WS and Shi
ZS: Overexpression of matrix metalloproteinase-9 is correlated with
carotid intraplaque hemorrhage in a swine model. J Neurointerv
Surg. 5:473–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stenvold H, Donnem T, Andersen S, Al-Saad
S, Al-Shibli K, Busund LT and Bremnes RM: Overexpression of matrix
metalloproteinase-7 and −9 in NSCLC tumor and stromal cells:
Correlation with a favorable clinical outcome. Lung Cancer.
75:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moss LA Shuman, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: Changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang B, Xie C, Zhong J, Chen H, Zhang H
and Wang X: A549 cell proliferation inhibited by RNAi mediated
silencing of the Nrf2 gene. Biomed Mater Eng. 24:3905–3916.
2014.PubMed/NCBI
|
|
20
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ong KJ, MacCormack TJ, Clark RJ, Ede JD,
Ortega VA, Felix LC, Dang MK, Ma G, Fenniri H, Veinot JG and Goss
GG: Widespread nanoparticle-assay interference: implications for
nanotoxicity testing. PLoS One. 9:e906502014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nijkamp MM, Span PN, Hoogsteen IJ, van der
Kogel AJ, Kaanders JH and Bussink J: Expression of E-cadherin and
vimentin correlates with metastasis formation in head and neck
squamous cell carcinoma patients. Radiother Oncol. 99:344–348.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z,
Sun J, Tan FW, Ding DP, Xu XH, Zhou F, et al: MicroRNA-92a promotes
lymph node metastasis of human esophageal squamous cell carcinoma
via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Q, Wang YD, Jing SH, Wang XL, Cheng YJ
and Wu FP: Expression of E-cadherin in nasopharyngeal carcinoma and
its relationship with cervical lymph node metastasis. Zhonghua
Zhong Liu Za Zhi. 32:425–428. 2010.(In Chinese). PubMed/NCBI
|
|
25
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reeves CV, Wang X, Charles-Horvath PC,
Vink JY, Borisenko VY, Young JA and Kitajewski JK: Anthrax toxin
receptor 2 functions in ECM homeostasis of the murine reproductive
tract and promotes MMP activity. PLoS One. 7:e348622012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
de Oliveira Demarchi AC, Zambuzzi WF,
Paiva KB, da Silva-Valenzuela M, Nunes FD, de Cássia Sávio Figueira
R, Sasahara RM, Demasi MA, Winnischofer SM, Sogayar MC and
Granjeiro JM: Development of secondary palate requires strict
regulation of ECM remodeling: Sequential distribution of RECK,
MMP-2, MMP-3, and MMP-9. Cell Tissue Res. 340:61–69. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu J, Ping W, Zu Y and Sun W:
Correlations of lysyl oxidase with MMP2/MMP9 expression and its
prognostic value in non-small cell lung cancer. Int J Clin Exp
Pathol. 7:6040–6047. 2014.PubMed/NCBI
|
|
29
|
Liao RG, Jung J, Tchaicha J, Wilkerson MD,
Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN,
et al: Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung
squamous cell carcinoma. Cancer Res. 73:5195–5205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Q, Jiang HO, Quan QL, Li J, He T and
Huang XS: Mutation analysis of FGFR3 gene in a family featuring
hereditary dwarfism. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.
28:705–707. 2011.(In Chinese). PubMed/NCBI
|
|
31
|
Sahlin P, Tarnow P, Martinsson T and
Stenman G: Germline mutation in the FGFR3 gene in a TWIST1-negative
family with Saethre-Chotzen syndrome and breast cancer. Genes
Chromosomes Cancer. 48:285–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haugsten EM, Wiedlocha A, Olsnes S and
Wesche J: Roles of fibroblast growth factor receptors in
carcinogenesis. Mol Cancer Res. 8:1439–1452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blick C, Ramachandran A, Wigfield S,
McCormick R, Jubb A, Buffa FM, Turley H, Knowles MA, Cranston D,
Catto J and Harris AL: Hypoxia regulates FGFR3 expression via
HIF-1α and miR-100 and contributes to cell survival in non-muscle
invasive bladder cancer. Br J Cancer. 109:50–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
